Skip to content
Subscriber Only

Pfizer Sees $26 Billion From Covid Shot, Big Potential Ahead

  • CEO sees vaccine having ‘durable demand’ moving forward
  • Drugmaker now expects $26 billion in vaccine sales in 2021
The Pfizer Inc. French headquarters in Paris.

The Pfizer Inc. French headquarters in Paris.

Photographer: Nathan Laine/Bloomberg
Updated on

Pfizer Inc. laid out a plan to turn its Covid-19 vaccine into a long-term business, clinching supply agreements that will yield $26 billion in sales this year while expanding the shot to children and developing new formulations that can combat variants and be stored more easily.

The drugmaker’s revenue forecast was an increase from $15 billion, reflecting the strong demand worldwide for a return to normalcy. Pfizer said it now expects to deliver 1.6 billion doses this year under contracts signed as of mid-April, with half the profits going to its partner in developing the shot, BioNTech SE.